FOLH1 and posterior cortical atrophy: As expected, patients with primary PCa or HS-BCR showed statistically significantly lower PSMA-TTVs than patients with mCRPC [177Lu]Lu-PSMA-617 therapy (p < 0.001; mean 10.39 mL, 462.42 mL, respectively).